



This is a repository copy of *Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/98515/>

Version: Supplemental Material

Article:

Pennington, B. and Davis, S. orcid.org/0000-0002-6609-4287 (2014) Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results. *Value in Health*, 17 (8). pp. 762-771. ISSN 1098-3015

<https://doi.org/10.1016/j.jval.2014.11.002>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Figure 1: PRISMA diagram for MedLine search

Figure 2: Incremental discounted quality-adjusted life years (QALYs) compared to disease modifying anti-rheumatic drugs (DMARDs)

Figure 3: Incremental cost-effectiveness ratios for rituximab versus disease modifying anti-rheumatic drugs (DMARDs) and abatacept versus rituximab

Figure 4: Cost-effectiveness plane and cost-effectiveness efficiency frontiers produced from sensitivity analysis for effect of each biologic on pain